GLP-1 Medication Denials Explained: Wegovy, Zepbound, Ozempic & Mounjaro | Appeals, Medicare Bridge & Next Steps Dr. Kulmeet Kundlas explains why GLP-1 agonist prescriptions (Wegovy, Zepbound, Ozempic, Mounjaro) are frequently denied and how patients can navigate the process. He distinguishes denials based on whether the drug is prescribed for weight loss versus metabolic health conditions such as diabetes, sleep apnea, and fatty liver/NASH/MASH, noting that coverage rules differ. He discusses high cash prices ($1,000–$1,400), employer benefit exclusions, and how insurers verify approved indications. He outlines Medicare Bridge Program weight-loss eligibility tiers by BMI and comorbidities, advises patients to demand written denial reasons, and notes denials are often reversed with proper evidence and timely appeals. He also covers physician-to-physician appeals, Bridge Program resubmission requirements, and manufacturer direct-purchase programs with escalating costs as doses increase.
Więcej odcinków z kanału "Primary Care Voice"
Nie przegap odcinka z kanału “Primary Care Voice”! Subskrybuj bezpłatnie w aplikacji GetPodcast.
